Mucosta
(Rebamipide)ApprovedSmall molecule
OtsukaRebamipide is used to treat dry eye disease by helping the eye produce more natural tears and protecting the eye's surface from damage.[2] Mucosta is currently approved and in use across 17 indications[4].[1]
Mucosta is one of 412 small molecule programs targeting Dyspepsia. It is currently in Approved.
17
Indications
25
Total Trials
0
Active Trials
411
Competitors
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 17 indications
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Mucosta
OtsukaApproved
Rituxan
RochePreclinical
Orencia
Bristol-Myers SquibbPreclinical
Cimzia
UCBPreclinical
Simponi
Johnson & JohnsonPreclinical
Enbrel
IImmunex
Preclinical
Remicade
OOrganon and Co
Preclinical
Arcoxia
NovartisPreclinical
Kevzara
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Ilaris
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Gastric Ulcer3 trials
Chronic Gastritis2 trials
Interaction2 trials
Rheumatoid Arthritis2 trials
14 more indications
Esophagitis1 trial
Combination Therapy1 trial
Non-steroidal Anti-inflammatory Drugs1 trial
Dyspepsia1 trial
Atrial Fibrillation1 trial
Prevention1 trial
Ulcerative Colitis1 trial
Keratoconjunctivitis sicca1 trial
Unspecified1 trial
h.Pylori Ttt With Rebamipide
Unknown status·—··NCT04550858·60 enrolled
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Mucosta drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Rebamipide. EMBL-EBI & Wellcome Sanger Institute.
- [5]